Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

David B. Page,Harry Bear,Sangeetha Prabhakaran,Margaret E. Gatti-Mays,Alexandra Thomas,Erin Cobain,Heather McArthur,Justin M. Balko,Sofia R. Gameiro,Rita Nanda,James L. Gulley,Kevin Kalinsky,Julia White,Jennifer Litton,Steven J. Chmura,Mei-Yin Polley,Benjamin Vincent,David W. Cescon,Mary L. Disis,Joseph A. Sparano,Elizabeth A. Mittendorf,Sylvia Adams
DOI: https://doi.org/10.1038/s41523-019-0130-x
2019-10-08
npj Breast Cancer
Abstract:Abstract Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.
oncology
What problem does this paper attempt to address?